BioSpace News Archive

Calyxt, Inc., a plant-based biotechnology platform company, announced that, in accordance with the offer letter entered into on July 15, 2021, it has granted, effective July 27, 2021, an inducement award to Michael A. Carr, Calyxt’s newly appointed President and Chief Executive Officer.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2021 financial results on Tuesday, August 3, 2021, after the close of US markets.

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, today announced the closing of a $63 million Series B financing.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2021 on Monday, August 9 at 4:30 p.m. ET / 1:30 p.m. PT.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that on July 27, 2021, the Board of Directors of the Company (the “Board”) approved a preliminary proposal for the potential dual listing of the Company’s newly issued shares on the Science and Technology Innovation Board of the Shanghai Stock Exchange (the “STAR Board”).

CEVEC Pharmaceuticals GmbH, the leading provider of high-performance cell technology for scalable manufacturing of advanced bio-therapeutics, announced the successful closing of an internal growth financing round.

Signifier Medical Technologies Ltd, a pioneer in patient-friendly therapies for sleep disordered breathing, announced that it has successfully raised $35 million in its Series D capital raise.

Aloe Care Health today announced that the United States Patent and Trademark Office (USPTO) issued Aloe Care Patent No: 11,064,339 for its Emergency Event Detection and Response System.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced data from a comparative study conducted by Eurofins Discovery showing commonality between its lead clinical compound MYMD-1 and three FDA-approved JAK inhibitor drugs for the treatment of autoimmune and inflammatory diseases.

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication of long-term follow-up data of the IMPACT Study, a multi-center randomized clinical trial of the Zephyr® Valves.